Takeda hikes full-year sales despite Actos erosion; NY union sues AbbVie, Teva, alleging pay-for-delay;

@FiercePharma: Behold the patent cliff: U.S. drug market shrinks for first time. Report | Follow @FiercePharma

@EricPFierce: Rapidly growing Sagent takes control of FDA approved China plant that is ready to produce products. More | Follow @EricPFierce

> Takeda Pharmaceutical managed to boost sales by 3% for fiscal 2012 to $15.8 billion, despite generic competition for its diabetes blockbuster Actos; its 2011 acquisition of Nycomed helped, though costs related to that buyout put a drag on net profits. Report

> A New York union benefits plan sued AbbVie ($ABBV) and Teva ($TEVA) over a patent settlement that allegedly delayed generic competition for AbbVie's cholesterol drug Niaspan. Report

> Warner Chilcott ($WCRX) said the FDA has approved its new oral contraceptive, as yet unnamed; the company plans to launch the new product in August. Release

> Hungary's Richter posted a 13.7% increase in first-quarter profits, thanks to growth in exports and new stability in its home market. Report

> Alexza Pharmaceuticals shares ($ALXA) jumped on the news that Teva Pharmaceutical Industries had hired on to sell its inhaled antipsychotic drug Adasuve. Report

> Novartis ($NVS) tapped Citigroup to handle the sale of shares in its Indian unit to reduce its stake in compliance with new regulatory guidelines. Report

Medical Device News

@FierceMedDev: Report: ICU weighing billion-dollar sale. Article | Follow @FierceMedDev

@MarkHFierce: Medtronic may have made waves with its renal denervation device, but buyers aren't widespread yet. More | Follow @MarkHFierce

 @DamianFierce: Vermillion is raising $31.5M in equity to market its ovarian cancer diagnostic. Story | Follow @DamianFierce

> Device tax, sluggish demand moves Theragenics Q1 into the red. More

> Nanostim reports early human success with leadless pacer. Story

> Genomic Health rolls out new prostate cancer Dx. DxExtra

Biotech News

@FierceBiotech: Industry Voices: Genomics, Biotechnology's Oldest Next Big Thing by Elizabeth Silverman. Story | Follow @FierceBiotech

@JohnCFierce: Cowen's Simos Simeonidis sees a stockholder revolt brewing at $VVUS. Numbers are incredibly ugly and execs have no idea what they are doing. | Follow @JohnCFierce

@RyanMFierce: Receptos made it through the gauntlet to complete $73M IPO, priced at low end of $14-$16 proposed range. Item | Follow @RyanMFierce

> FDA's Hamburg touts rising approval record and promises swifter interaction. Story

> Global CRO Quintiles rakes in $947M as its hot IPO sells at top range. News

> Trevena lands $430M Forest deal, $60M venture round as heart drug heads to PhIIb. Article

Vaccines News

> CDC continues to build defenses in H7N9 lull. More

> GSK, Merck agree on HPV vax discount with GAVI. Article

> Heroin vaccine keeps rats clean. Item

> Sanofi sees Shantha Biotech's Shan5 back in 2014. Report

> Takeda takes on Sanofi with $250M dengue buyout. More

Pharma Manufacturing News

> Pediatric drug shortages draw Congressional attention. News

> Hamburg faces Senate as new compounding regulations progress. Story

> Proposed law would delay unit drug tracking for 15 years. More

> Ranbaxy sees tough quarter as it recovers from manufacturing mess. Article

And Finally... France reported its first case of a novel coronavirus, similar to SARS, that has been spreading in Saudi Arabia. Report

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.